MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
21.30
-0.30
-1.39%
After Hours: 21.15 -0.15 -0.71% 19:16 12/26 EST
OPEN
21.73
PREV CLOSE
21.60
HIGH
21.73
LOW
21.07
VOLUME
906.16K
TURNOVER
--
52 WEEK HIGH
22.73
52 WEEK LOW
8.58
MARKET CAP
1.85B
P/E (TTM)
-5.9076
1D
5D
1M
3M
1Y
5Y
1D
2025 Performance Review And Future Strategy
Seeking Alpha · 4d ago
Weekly Report: what happened at SNDX last week (1215-1219)?
Weekly Report · 5d ago
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
TipRanks · 12/19 22:09
Syndax Pharmaceuticals Moves to Uncertificated Shares
Reuters · 12/19 21:31
Syndax Pharmaceuticals (SNDX): Assessing Valuation After Key ASH Data on Revuforj and Niktimvo
Simply Wall St · 12/18 03:19
Syndax Pharma: Continuing Execution In AML
Seeking Alpha · 12/17 13:15
Can Revuforj’s Awards Momentum Redefine Syndax Pharmaceuticals’ (SNDX) Precision Oncology Investment Narrative?
Simply Wall St · 12/16 22:17
Weekly Report: what happened at SNDX last week (1208-1212)?
Weekly Report · 12/15 09:59
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.